PD 147953Alternative Names: FR 139317
Latest Information Update: 17 Apr 2002
At a glance
- Originator Fujisawa
- Mechanism of Action Endothelin A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cerebrovascular disorders; Coronary disorders; Diabetic nephropathies; Heart failure; Hypertension; Ischaemic heart disorders; Myocardial infarction; Renal failure